Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolamolol SCHEMBL613511 | 1.00 | ATM (0.59) | ATMADRB2ADRB1CYP1A2ADRB3 | |
| Tolamolol SCHEMBL8057907 | 0.99 | ATM (0.58) | ATMADRB2ADRB1CYP1A2ADRB3 | |
| SCHEMBL11543785 | 0.87 | ADRB2 (0.56) | ATMADRB2ADRB1CYP1A2ADRB3 | |
| SCHEMBL11545627 | 0.85 | KDM4E (0.53) | ATMADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL11355780 | 0.85 | ATM (0.59) | ATMADRB2ADRB1CYP1A2ADRB3 | |
| SCHEMBL11357355 | 0.85 | ATM (0.59) | ATMADRB2ADRB1CYP1A2ADRB3 | |
| SCHEMBL11550951 | 0.85 | KDM4E (0.52) | ATMADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL11550848 | 0.85 | CYP3A4 (0.54) | ATMADRB2ADRB1CYP1A2ADRB3 | |
| SCHEMBL10713963 | 0.85 | ADRB2 (0.58) | ATMADRB2ADRB1CYP1A2ADRB3 | |
| SCHEMBL11545209 | 0.84 | ATM (0.53) | ATMADRB2ADRB1CYP1A2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1064 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | claimed |
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2017-01-05 | — | — | US | claimed |
| US-9498481-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | claimed |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-07-07 | — | — | US | claimed |
| US-9255104-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2014-09-25 | — | — | US | claimed |
| US-5093126-A | Sustained release, beta blockers | ALCON LABORATORIES, INC. (US) | 1992-03-03 | — | — | US | claimed |
| EP-0429732-A1 | Sustained-release compositions containing cation exchange resins and polycarboxylic polymers | ALCON LABORATORIES, INC. (US) | 1991-06-05 | — | — | EP | claimed |
| EP-0366765-A4 | ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF SYMPATHOMIMETIC AGENTS AND BETA-1 SELECTIVE BETA-BLOCKERS | — | 1990-12-05 | — | — | EP | claimed |
| EP-0366765-A1 | ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF SYMPATHOMIMETIC AGENTS AND BETA-1 SELECTIVE BETA-BLOCKERS. | ALCON LAB INC (US) | 1990-05-09 | — | — | EP | claimed |
| WO-1989010120-A1 | ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF SYMPATHOMIMETIC AGENTS AND BETA-1 SELECTIVE BETA-BLOCKERS | ALCON LABORATORIES, INC. (US) | 1989-11-02 | — | — | WO | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0105996-A1 | Ophthalmic compositions for treating elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-04-25 | — | — | EP | claimed |
| US-4303637-A | Medication indicated for ocular hypertension | ALZA CORPORATION (US) | 1981-12-01 | — | — | US | claimed |
| EP-0037622-A2 | Drug delivery insert for controlled ocular therapy | ALZA CORPORATION (US) | 1981-10-14 | — | — | EP | claimed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | ATM 4332/4885ADRB2 180/4885ADRB1 152/4885 |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | ATM 4332/4885ADRB2 180/4885ADRB1 152/4885 |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | ATM 3791/4885ADRB2 3813/4885ADRB1 3375/4885 |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | ATM 4332/4885ADRB2 180/4885ADRB1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.